Meeting
2015 ASCO Annual Meeting
Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Authors
Jonathan R. Strosberg
Moffitt Cancer Center, Tampa, FL
Jonathan R. Strosberg , Mauro Cives , Marjorie Brelsford , Michael Black , Alan Meeker , Masoumeh Ghayouri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4099)
DOI
10.1200/jco.2015.33.15_suppl.4099
Abstract #
4099
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.
First Author: Heloisa P. Soares
Poster
2019 Gastrointestinal Cancers Symposium
Determination of O-6-methylguanine-DNA methyltransferase by immunochemistry and pyrosequencing as a predictive factor of response to temozolomide in pancreatic neuroendocrine tumors.
First Author: Roberto Escala
Poster
2017 Gastrointestinal Cancers Symposium
Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes.
First Author: Samer Alsidawi
Poster
2015 ASCO Annual Meeting
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
First Author: Pamela L. Kunz